Invivyd (IVVD) said Friday its investigational monoclonal antibody Pemgarda has been added to the National Comprehensive Cancer Network's clinical practice guidelines in oncology for B-cell lymphomas.
The product's inclusion in the cancer non-profit's guidelines recognizes it as a potential option for pre-exposure prophylaxis against COVID-19 in patients with B-cell malignancies, the company said.
The company's shares were up 10% in recent premarket activity on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.